

Recombinant Mouse Interleukin-3 (IL-3)

Publication Number MAN00003407

Revision Date 03 May 2011

Catalog Number:	PMC0034	PMC0035	PMC0031	PMC0033	
Quantity:	10 μg	25 μg	100 µg	1 mg	
Lot Number:	See product label.				
Molecular Weight:	16.1 kDa, 144 amino acid residues				
Purity:	>95% as determined by SDS-PAGE analysis.				
Amino Acid Sequence:	ASISGRDTHR LTRTLNCSSI VKEIIGKLPE PELKTDDEGP SLRNKSFRRV NLSKFVESQG EVDPEDRYVI KSNLQKLNCC LPTSANDSAL PGVFIRDLDD FRKKLRFYMV HLNDLETVLT SRPPQPASGS VSPNRGTVEC				
Biological Activity:	ED_{50} range = 0.01–0.1 ng/mL (Specific Activity: 1.0×10^8 – 1.0×10^7 units/mg), determined by the dose dependent proliferation of NFS-60 cells. Optimal concentration for individual application should be determined by a dose response assay.				
Formulation:	Lyophilized, carrier free.				
Sterility:	Filtered prior to lyophilization through a 0.22 micron sterile filter.				
Endotoxin:	<0.1 ng/μg				
Production:	Recombinant mouse IL–3 is produced in <i>E. coli</i> and purified via sequential chromatography.				
Reconstitution Recommendation:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Lyophilized mIL–3 should be reconstituted in deionized water to 0.1–1.0 mg/mL to regain full activity. These stock solutions should be apportioned into working aliquots and stored at ≤–20°C. Further dilutions should be made in low endotoxin medium or buffered solution with FBS or tissue culture grade BSA.				
Suggested Working Dilutions:	The optimal concentration should be determined for each specific application.				
Storage:	Lyophilized mIL -3 should be stored at 2°C to 8°C, preferably desiccated. Store reconstituted mIL -3 at ≤ -20 °C (not in a frost-free freezer). Keep freeze-thaw cycles to a minimum.				
Expiration Date:	Expires one year from date of receipt when stored as instructed.				
		opadhyay, E.H. Bresnick, B.S. Pace, K. Van DeMark, B.H. Zhang, D.V. Faller, and S.P. nain fatty acid derivatives stimulate cell proliferation and in duce STAT–5 activation.			
	Burgess, W., K. Jesse, Q.S. T and the cytokines IL–3 and J. Neuroimmunol. 135(1–2	d IL–4 promote survival of pr	er and K.W. Kelley (2003) Inst ogenitor myeloid cells by diffe	ulin-like growth factor–I erent mechanisms.	
	Cattaneo, E., C. De Fraja, L. Conti, B. Reinach, L. Bolis, S. Govoni, and E. Liboi (1996) Activation of the JAK/STAT pathway leads to proliferation of ST14A central nervous system progenitor cells. J. Biol. Chem. 271(38):23374–23379.				
	Chou, C.C., J.S. Fine, C. Pugliese-Sivo, W. Gonsiorek, L. Davies, G. Deno, M. Petro, M. Schwarz, P.J. Zavodny, and R.W. Hipkin (2002) Pharmacological characterization of the chemokine receptor, hCCR1 in a stable transfectant and differentiated HL-60 cells: antagonism of hCCR1 activation by MIP–1 beta. British Journal of Pharmacology 137(5):663–675.				
	Cox, M.A., C.H. Jenh, W. Gonsiorek, J. Fine, S.K. Narula, P.J. Zavodny, and R.W. Hipkin (2001) Human interferoninducible 10–kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: Differential binding to receptor states. Mol. Pharmcol. 59(4):707–715.				
	Crouse, J.A., G.E. Elliott, T.L. Burgess, L. Chiu, L. Bennett, J. Moore, M. Nicolson, and R.E. Pacifici (1998) Altered cell surface expression and signaling of leptin receptors containing the fatty mutation. J. Biol. Chem. 273(29):18365–73.				
	Giver, C.R., R. Wong, D.H. Moore, and M.G. Pallavicini (2001) Persistence of aneuploid immature/primitive hemopoietic sub–populations in mice 8 months after benzene exposure in vivo. Mutation Res. 491:127–138.				

References, continued:

- Gu, H., J.D. Griffin, and B.G. Neel (1997) Characterization of two SHP–2-associated binding proteins and potential substrates in hematopoietic cells. J. Biol. Chem. 272(26):16421–30.
- Hirai, I. and H.G. Wang (2001) Survival–factor-induced phosphorylation of Bad results in its dissociation from Bcl–X-L but not Bcl-2. Biochem. J. 359:345–352.
- Jones, M., M. Komatsu, and R.B. Levy (2000) Cytotoxically impaired transplant recipients can efficiently resist major histocompatibility complex-matched bone marrow allografts. Biol. Blood Marrow Transplantation 6 (4A):456–464.
- Mirmonsef, P., C.P. Shelburne, C.F. Yeatman, H.J. Chong, and J.J. Ryan (1999) Inhibition of Kit expression by IL–4 and IL-10 in murine mast cells: Role of STAT6 and phosphatidylinositol 3 '-kinase. J. Immunol. 163(5):2530–2539.
- Nakoinz, I., M.T. Lee, J.F. Weaver, and P. Ralph (1990) Differentiation of the IL-3-dependent NFS-60 cell line and adaption to growth in macrophage colony-stimulating factor. J. Immunol. 145(3):860–864.
- Robbins, P., D. Skelton, X.-J. Yu, S. Halene, E. Leonard, and D. Kohn (1998) Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc. Nat'l. Acad. Sci. 95(17):10182–10187.
- Rubinson, D.A., C.P. Dillon, A.V. Kwiatkowski, C. Sievers, L.L. Yang, J. Kopinja, M.D. Zhang, M. T. McManus, F. B. Gertler, M. L. Scott and L. Van Parijs (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nature Genetics 33(3):401–406.
- Tajima, Y., E.J. Huang, K. Vosseller, M. Ono, M.A. Moore, and P. Besmer (1998) Role of dimerization of the membrane–associated growth factor kit ligand in juxtacrine signaling: the Sl17H mutation affects dimerization and stability-phenotypes in hematopoiesis. J. Exp. Med. 187(9):1451–1461.
- Tajima, Y., M. Moore, V. Soares, M. Ono, H. Kissel, and P. Besmer (1998) Consequences of exclusive expression in vivo of kit–ligand lacking the major proteolytic cleavage site. Proc. Nat'l. Acad. Sci. 95(20):11903–11908.
- Taylor, M.A., P.M. Chaudhary, J. Klem, V. Kumar, J.D. Schatzle, and M. Bennett (2001) Inhibition of the death receptor pathway by cFLIP confers partial engraftment of MHC class I–deficient stem cells and reduces tumor clearance in perforin–deficient mice. J. Immunol. 167(8):4230–4237.
- Yeatman, C.F., S.M. Jacobs–Helber, P. Mirmonsef, S.R. Gillespie, L.A. Bouton, H.A. Collins, S.T. Sawyer, C.P. Shelburne, J.J. Ryan (2000) Combined stimulation with the T helper cell type 2 cytokines interleukin (IL)–4 and IL-10 induces mouse mast cell apoptosis. J. Exp. Med. 192(8):1093–1103.
- Zhou, J.H., S.R. Broussard, K. Strle, G.G. Freund, R.W. Johnson, R. Dantzer, and K.W. Kelley (2001) IL–10 inhibits apoptosis of promyeloid cells by activating insulin receptor substrate–2 and phosphatidylinositol 3 '-kinase. J. Immunol. 167(8):4436–4442.

Explanation of Symbols

The symbols present on the product label are explained below:

Symbol	Description	
REF	Catalog Number	
RUO	Research Use Only	
	Use by	
	Manufacturer	
[-]	Without, does not contain	
from Light	Protect from light	
<u> </u>	Directs the user to consult instructions for use (IFU), accompanying the product.	

Symbol	Description		
LOT	Batch code		
IVD	In vitro diagnostic medical device		
	Temperature limitation		
EC REP	European Community authorized representative		
[+]	With, contains		
\triangle	Consult accompanying documents		

Limited Use Label License: Research Use Only

The purchase of this product conveys to the purchaser the limited, non-transferable right to use the purchased amount of the product only to perform internal research for the sole benefit of the purchaser. No right to resell this product or any of its components is conveyed expressly, by implication, or by estoppel. This product is for internal research purposes only and is not for use in commercial applications of any kind, including, without limitation, quality control and commercial services such as reporting the results of purchaser's activities for a fee or other form of consideration. For information on obtaining additional rights, please contact outlicensing@lifetech.com or Out Licensing, Life Technologies, 5791 Van Allen Way, Carlsbad, California 92008.

For Research Use Only. Caution: Not for human or animal therapeutic or diagnostic use.

Manufactured under ISO 13485 Quality Standard

 $Manufacturing \ site: 7335 \ Executive \ Way \ | \ Frederick, \ MD \ 21704 \ | \ Toll \ Free \ in \ USA \ 800.955.6288 \ .$

© 2011 Life Technologies Corporation. All rights reserved. The trademarks mentioned herein are the property of Life Technologies Corporation or their respective owners.

For support visit www.lifetechnologies.com/support or email techsupport@lifetech.com

life technologies™